PellePharm Overview

  • Year Founded
  • 2012

Year Founded

  • Status
  • Private

  • Employees
  • 8

Employees

  • Latest Deal Type
  • 2ndary - Private

  • Investors
  • 7

PellePharm General Information

Description

Developer of skin cancer therapeutics intended to mitigate the tumor burden with basal cell carcinomas. The company's therapeutics include topical hedgehog inhibitor which decreases the number of surgically-eligible basal cell carcinomas in Gorlin syndrome patients, enabling healthcare providers to treat cancer by potentially reducing invasive and painful surgeries.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Discovery Tools (Healthcare)
Corporate Office
  • 101 Mission Street
  • Suite 2050
  • San Francisco, CA 94105
  • United States
+1 (510) 000-0000

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

PellePharm Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
7. Secondary Transaction - Private 01-Apr-2023 00000 Completed Startup
6. Later Stage VC 20-Nov-2018 0000 00000 Completed Startup
5. Later Stage VC (Series C) 18-Jun-2018 00.00 000.00 00000 Completed Startup
4. Debt - General 29-Mar-2018 00.00 000.00 Completed Startup
3. Later Stage VC (Series B2) 31-Jul-2017 0000 000.00 0000 Completed Startup
2. Early Stage VC (Series B) 23-Jul-2015 $4.55M $7.67M 000.00 Completed Startup
1. Early Stage VC (Series A) 11-May-2015 $3.12M $3.12M 00.00 Completed Startup
To view PellePharm’s complete valuation and funding history, request access »

PellePharm Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series C 0,000,000 00.000000 00.00 00.00 00.00 00 00.00 0.000
Series B2 00,000,000 00.000000 00.00 00.00 00.00 00 00.00 00.000
Series B 3,888,889 $0.000100 $0.09 $1.17 $1.17 1x $1.17 8.67%
Series A 3,712,649 $0.000100 $0.84 $0.84 1x $0.84 8.27%
To view PellePharm’s complete cap table history, request access »

PellePharm Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of skin cancer therapeutics intended to mitigate the tumor burden with basal cell carcinomas. The company's th
Drug Discovery
San Francisco, CA
8 As of 2021
00000
00000000000 00000

00 000

prehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Exce
0000 000000000
Burnaby, Canada
00 As of 0000
000.00
0000000000 000.00

000000

iusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veni
0000 000000000
Boston, MA
0000 As of 0000
00.000
0000 0000-00-00
000000&0
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

PellePharm Competitors (20)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Qu Biologics Venture Capital-Backed Burnaby, Canada 00 000.00 0000000000 000.00
Vertex Pharmaceuticals Formerly VC-backed Boston, MA 0000 00.000 000000&0
Bolden Therapeutics Venture Capital-Backed Providence, RI 0 00.00 000000000 00.00
Naked Biome Formerly VC-backed San Francisco, CA 0 000.00 000000&0 000.00
F2G Venture Capital-Backed Manchester, United Kingdom 00 00000 0000000000 0 00000
You’re viewing 5 of 20 competitors. Get the full list »

PellePharm Patents

PellePharm Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20170231968-A1 Method for relief of and treatment of pruritus Inactive 11-Feb-2016 00000000000 0
JP-6796638-B2 Topical formulations and their use for the delivery of hedgehog inhibitory compounds Active 04-Jun-2015 0000000000
JP-2018516989-A Topical formulations for the delivery of hedgehog inhibitory compounds and uses thereof Active 04-Jun-2015 0000000000
JP-2021014469-A Topical formulations for delivery of hedgehog inhibitor compounds and uses thereof Pending 04-Jun-2015 A61K31/496 0

PellePharm Executive Team (7)

Name Title Board Seat Contact Info
Sanuj Ravindran MD President & Board Member
Sharon Kokubun Vice President of Finance & Controller
Ervin Epstein MD Co-Founder, Chief Medical Officer, Medical Advisor, Physician & Board Member
Jean Tang MD Co-Founder, Board Member & Medical Advisor
Philip Beachy Ph.D Co-Founder
You’re viewing 5 of 7 executive team members. Get the full list »

PellePharm Board Members (7)

Name Representing Role Since
Anders Kronborg LEO Pharma Board Member 000 0000
Eric Aguiar MD Aisling Capital Board Observer 000 0000
Frank McCormick Ph.D Self Board Member 000 0000
Jean Tang MD PellePharm Co-Founder, Board Member & Medical Advisor 000 0000
Neil Kumar Ph.D BridgeBio Pharma Board Member 000 0000
You’re viewing 5 of 7 board members. Get the full list »

PellePharm Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

PellePharm Investors (7)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
LEO Pharma PE-Backed Company Minority 000 0000 000000 0
Aisling Capital Venture Capital Minority 000 0000 000000 0
EcoR1 Capital Venture Capital Minority 000 0000 000000 0
Mark De Souza Angel (individual) Minority 000 0000 000000 0
BridgeBio Pharma Corporation Minority 000 0000 000000 0
You’re viewing 5 of 7 investors. Get the full list »

PellePharm Subsidiaries (1)

Company Name Industry Location Founded
PellePharm (Hedgehog Signaling Pathway Blocker in San Francisco) Buildings and Property San Francisco, CA
To view PellePharm’s complete subsidiaries history, request access »

PellePharm FAQs

  • When was PellePharm founded?

    PellePharm was founded in 2012.

  • Who is the founder of PellePharm?

    Ervin Epstein MD, Jean Tang MD, Philip Beachy Ph.D, and Michael Henderson MD are the founders of PellePharm.

  • Where is PellePharm headquartered?

    PellePharm is headquartered in San Francisco, CA.

  • What is the size of PellePharm?

    PellePharm has 8 total employees.

  • What industry is PellePharm in?

    PellePharm’s primary industry is Drug Discovery.

  • Is PellePharm a private or public company?

    PellePharm is a Private company.

  • What is PellePharm’s current revenue?

    The current revenue for PellePharm is 000000.

  • How much funding has PellePharm raised over time?

    PellePharm has raised $113M.

  • Who are PellePharm’s investors?

    LEO Pharma, Aisling Capital, EcoR1 Capital, Mark De Souza, and BridgeBio Pharma are 5 of 7 investors who have invested in PellePharm.

  • Who are PellePharm’s competitors?

    Qu Biologics, Vertex Pharmaceuticals, Bolden Therapeutics, Naked Biome, and F2G are some of the 20 competitors of PellePharm.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »